Dow-Mu Koh1, Keiko Miyazaki2,
Matthew Orton2, Toni Wallace1, David J. Collins2,
Martin O. Leach2, Val Lewington3
1Department of Radiology, Royal Marsden
NHS Foundation Trust, Sutton, Surrey, United Kingdom; 2CRUK-EPSRC
Cancer Imaging Centre, Institute of Cancer Research, Sutton, Surrey, United
Kingdom; 3Department of Nuclear Medicine, Royal Marsden NHS
Foundation Trust, Sutton, Surrey, United Kingdom
We
investigated diffusion-weighted MR imaging (DW-MRI) for assessing treatment
response of liver metastases of neuroendocrine origin to targeted
radiolabelled therapy 90Y-DOTATOC. The quantitative apparent diffusion
coefficient (ADC) appears to be a promising response and prognostic
biomarker. Responders were found to have a lower pre-treatment value compared
with non-responders; and also demonstrated a significant increase in ADC at 2
months after the first cycle of treatment. Response defined by ADC changes
also showed good agreement with biochemical response.